Foundation Medicine to support enrolment for Kura Oncology ’s SCCHN trials

US-based biopharmaceutical firm Kura Oncology has signed a collaboration agreement with Foundation Medicine to support patient enrolment into its clinical programme of tipifarnib to treat relapsed and / or refractory HRAS mutant squamous cell carcino …
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news